Novartis NOVN0.33%increase; green up pointing triangle said it is launching a direct-to-patient platform in the U.S. to sell a discounted version of its Cosentyx drug, the latest big pharma company to ...
8don MSN
Cidara signals over 100M U.S. patient opportunity as CD388 Phase III trial enrollment expands
Q3 2025 Management View CEO Jeffrey Stein reported that "our lead candidate, CD388 has advanced into Phase III development on ...
Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways. At a recent Institute for Value-Based Medicine ® event in Houston, Hans Lee, MD, ...
MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
To decipher the mechanisms underlying the protective role of the Mediterranean diet (MED) in Crohn's disease (CD), we explored the implications of adherence to MED on CD course, inflammatory markers, ...
CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback